Omeros Is Gaining Momentum With A Diverse Pipeline Summary
•Omeros has one of the most diverse pipelines for a junior biotech out there at present, giving it multiple potential areas for success.
•Omidria is gaining sales year over year and has lots of room to grow ahead of it, giving Omeros a potential positive cash flow generating product to fund pipeline development.
•OMS721, the furthest advanced pipeline candidate, continues to show promise and if approved, can unlock significant value for the company and its shareholders in the near future. Omeros Corporation (NASDAQ:OMER) is a junior biotech with big goals, and a large portfolio of drug candidates, that's already generating growing revenues as it looks to fund the development of its potential blockbuster treatments. With 12 programs under development (both clinical and pre clinical), there's a lot of potential here, and the share price has been climbing to near all time highs on the back of recent positive developments. That being said, this might just be the beginning of what could turn out to be a company with significant revenue generating ability in the next few years.
Been in this since it was 6$ and some change. Rode it up and down through the last big bump but took a little profit to replace my car with a new one before it dropped below 25. Got back in with more when it went below 10 and here we are right back up. But!! this time there is a whole new ball game with FDA's status verifying 701 not only works but is a breakthrough. No more selling for me now. At least till I retire or maybe when it breaks $100 then I might have to take a little off the top to celebrate. I am in for the long haul now. GTLA
A 30-month stay of the FDA's approval? As a result of this suit? Each stay is expected to remain in effect until NOVEMBER, 2019? So no FDA approval for at least another 17 months, is that correct?
OMER sues Sandos..
Omeros Corp. (OMER) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 16, 2017.
On June 21, 2017, Omeros filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware and a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz Inc., or Sandoz, and on June 22, 2017, Omeros filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware and a patent infringement lawsuit in the U.S.
Not liking the volume on this sharp decline
What a turn around! If this closes near $27 the shorts will lose big time and I don t see how they are hedging this unless they cover and reset which is a losing scenario! Bad consequences will occur and hopefully their are no jumping off high places!
Next stop $30
Got in a little late had my account frozen for some weird unresolved reason. Anyway average price paid is 24.75. From my research I can only assume this stock should hit $30-45? Just my opinion, any thoughts? Did I get in too late?
Ok I dont know why my post was deleted, but I will post it again. Looking at some of the other biotech companies like ALXN...I realize how much bigger price wise we can be than them. Right now ALXN has an inferior product compared to OMS721. If we get FDA approval on that drug alone we could easily blow by $125 a share. Can you imagine having approvals on 721, 824 and 405? With the revs they could generate we could easily be a $500+ stock with splits. Think about this....OMER has almost 50 million shares outstanding. ALXN with an inferior product and almost 225 million shares outstanding is about $120 a share. Anyone here disagreeing with me please state your case. If I am wrong.... I am wrong. But I guess we will soon see.
This guy is a seeking alpha writer who actually gets paid. Here's his take when OMER was $5. Alwasy do your own DD, most of these guys are clueless
Stephen Simpson, CFA Long only, growth at reasonable price, value, research analyst Omeros Doesn't Look Like That Much Of An Opportunity Biotechnology is hard enough all on its own without investors complicating things with low-potential drugs in difficult markets. With that in mind, I don't see significant opportunity in Omeros (OMER). The company's near-term pipeline for ophthalmology and knee surgery isn't all that promising, and the early-stage pipeline of MASP-2, PDE10, PDE7, GPCR, and PPAR-gamma has far too little supporting data at this point to validate a high valuation or multiple.
very nice run so far,Jun 09, 2017 14.95 15.44 14.86 15.29 15.29 514,400
Almost a $1 swing in first 4 minutes. Talk about high activity
More good news coming soon
Maybe time for a breather? Would not be surprised here.
It looks like all the employees and board directors want to participate and think that they have a home run drug.
looks like all remaining shorts will get drilled again
But according to reports from Kaiser Health News and Politico, the Trump administration is preparing an executive order that's shaping up to be a lot more favorable to drug companies. And on Tuesday, The New York Times reported on the contents of a draft of the executive order, reaffirming the administration's likely more relaxed, industry-friendly stance on drug pricing. That sent the biotech index soaring again on Wednesday.
Morgan Stanley attributed some of biotech's strength to a shift in investors out of the energy sector and into biotech and tech, as well as some company-specific good news.
IgA, lupus nephritis, aHus, other vasculitis ANCA positive ones,....there are too many indications for this drug as complement mediated autoimmune diseases are many. Could be for asthma and glomerulonephritis. This company will be huge
So what will be next as we got FDA BDT,
ben 9 days ago
Could it be FDA breakthrough designation, European partner, run up into the ASM, or something else?
Harry Boxer has posted his Charts of the Day video on OMER at TheTechTrader site noting: Omeros Corporation (OMER) is looking really good. It gained another 1.69, or 7%, to 26.58, on 1.3 million shares traded. It has recently gone from 16 to 26.63 in about a week and a half. There’s a possibility we could see 29-29.50. It has 16.4 days to cover.